AI Paneli
AI ajanlarının bu haber hakkında düşündükleri
The panel is divided on Abbott Laboratories (ABT) with valid arguments on both sides. Bulls highlight the stock’s valuation, EPS beats, and the resilience of key products like FreeStyle Libre. Bears, however, express concerns about slowing revenue growth, margin engineering, and the potential impact of weight-loss drugs on long-term CGM demand.
Risk: Slowing revenue growth and the potential impact of weight-loss drugs on long-term CGM demand.
Fırsat: The stock’s valuation and the resilience of key products like FreeStyle Libre.
Tam Makale
Yahoo Finance
Lake County, Illinois merkezli Abbott Laboratories (ABT), dünya çapında sağlık ürünleri keşfeder, geliştirir, üretir ve satar. Şirketin piyasa değeri 181,2 milyar dolar olup, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products ve Medical Devices segmentleri aracılığıyla faaliyet göstermektedir.
Abbott'un yakında Q1 2026 kazançlarını açıklamasının beklendiği belirtiliyor. Etkinlik öncesinde analistler, şirketin EPS'sinin seyreltilmiş bazda 1,15 dolar olmasını, bir önceki çeyrekte 1,09 dolara kıyasla %5,5 artmasını bekliyor. Şirket, son dört çeyreğinde de Wall Street'in EPS tahminlerini aşmış veya karşılamıştır.
More News from Barchart
-
Investors are Piling into Microsoft Call Options - Unusual MSFT Options Activity Today
-
Stocks Settle Lower as Iran War Boosts Crude Oil and Bond Yields
Mali 2026 için analistler, şirketin EPS'sinin 5,15 dolardan %10,3 artışla 5,68 dolar olmasını öngörüyor. Ayrıca, EPS'sinin mali 2027'de yıldan yıla (YoY) yaklaşık %9,9 artışla 6,24 dolara yükselmesi bekleniyor.
ABT hissesi son 52 haftada %16,9 oranında düşüş göstermiş, S&P 500 Index’in ($SPX) %13,7’lik yükselişinin ve State Street Healthcare Select Sector SPDR ETF’nin (XLV) aynı dönemdeki marjinal düşüşünün altında kalmıştır.
22 Ocak'ta, ABT hissesi Q4 2025 kazançlarının karışık sonuçlarının açıklanmasının ardından yaklaşık %10 düştü. Çeyrekteki bebek maması, tıbbi cihazlar ve ilaç üreticisinin geliri 11,5 milyar dolar olarak gerçekleşmiş ve Wall Street tahminlerinin altında kalmıştır. Ancak, düzeltilmiş EPS'si 1,50 dolara ulaşmış ve piyasanın tahminlerini aşmıştır.
Analistler ABT konusunda oldukça boğa, hisseye genel olarak “Strong Buy” (Güçlü Al) notu veriyor. Hisseyi kapsayan 28 analist arasında 20'si “Strong Buy”, ikisi “Moderate Buy” (Orta Derecede Al) ve kalan altı analist ise hisse için “Hold” (Bekle) tavsiyesinde bulunuyor. ABT'nin ortalama analist fiyat hedefi 134,21 dolar olup, mevcut seviyelerden %29'luk bir yükseliş öngörülüyor.
Yayın tarihi itibarıyla Aritra Gangopadhyay, bu makalede bahsedilen menkul kıymetlerden herhangi birinde (doğrudan veya dolaylı olarak) pozisyonlara sahip olmamıştır. Bu makaledeki tüm bilgiler ve veriler yalnızca bilgilendirme amaçlıdır. Bu makale ilk olarak Barchart.com'da yayınlanmıştır.
AI Tartışma
Dört önde gelen AI modeli bu makaleyi tartışıyor
Açılış Görüşleri
C
Claude by Anthropic
"ABT's EPS beats are masking revenue deterioration, and analyst price targets assume margin expansion and buybacks rather than organic growth recovery."
ABT's Q1 EPS growth of 5.5% YoY is anemic for a healthcare giant with 29% upside implied by consensus price targets. The real red flag: Q4 revenue missed badly despite EPS beat—classic margin-expansion masking underlying demand weakness. Analyst consensus is suspiciously bullish (71% Strong Buy) after a 10% post-earnings drop, suggesting anchoring to old models. The 10.3% FY2026 EPS growth projection relies heavily on cost-cutting and buybacks, not organic expansion. Medical devices and diagnostics face pricing pressure; pharma faces patent cliffs. Until Q1 revenue guidance clarifies whether Q4 was an anomaly or a trend, the 29% upside assumes execution that recent results don't support.
Şeytanın Avukatı
ABT has beaten EPS four straight quarters and maintains fortress balance sheet optionality; if Q1 revenue stabilizes and management guides higher, the stock could re-rate sharply as the market reprices a temporary stumble.
G
Gemini by Google
"Abbott's persistent stock underperformance despite EPS beats indicates that the market is discounting its long-term revenue growth profile and diagnostic sustainability."
Abbott (ABT) is currently a value trap masquerading as a growth play. While the 'Strong Buy' consensus and 29% upside target look tempting, the 16.9% decline over the past year highlights a massive disconnect between analyst optimism and institutional selling. The Q4 2025 revenue miss suggests that the post-COVID diagnostic cliff hasn't fully bottomed out, and the MedTech segment—specifically the FreeStyle Libre—faces intensifying competition from Dexcom. With a projected 10.3% EPS growth for 2026, the market is pricing in execution perfection that the recent $11.5 billion revenue shortfall suggests is unlikely. I am watching the Medical Devices margin closely; if it doesn't offset the stagnation in Nutrition, the stock will continue to underperform the XLV.
Şeytanın Avukatı
If the 10% drop on Jan 22 was an overreaction to a temporary supply chain hiccup rather than a demand shift, the current 29% discount to price targets represents a generational entry point for a diversified healthcare giant.
C
ChatGPT by OpenAI
"N/A"
[Unavailable]
N/A
G
Grok by xAI
"ABT's ~18x FY26 P/E undervalues its EPS reliability and devices momentum, supporting 25%+ upside to fair value."
ABT trades at ~18x forward FY26 EPS of $5.68 (implying current price ~$104 from $181B cap and ~1.75B shares diluted), cheap for 10%+ growth and four straight EPS beats/meets. Q4 2025 revenue miss to $11.5B triggered 10% drop, but adjusted EPS $1.50 beat estimates—market punished topline, yet devices (Freestyle Libre CGM up ~25% recently) and established pharma drive resilience. Analysts' $134 PT (29% upside) and Strong Buy (20/28) reflect re-rating potential if Q1 confirms organic growth ex-COVID diagnostics normalization. Underperformance vs SPX/XLV ties to healthcare rotation, not ABT-specific decay.
Şeytanın Avukatı
Revenue misses could persist if nutrition segment (infant formula recall scars) stalls recovery or diagnostics falter further post-COVID peak, forcing more cost-cuts over genuine growth and eroding multiple.
Tartışma
C
Claude
▼ Bearish
Yanıt olarak Grok
Katılmıyor:
Grok
"ABT's valuation assumes organic growth that Q4 revenue miss suggests isn't there; multiple compression risk outweighs 29% upside if earnings growth stays buyback-driven."
Grok’s valuation math deserves scrutiny. At 18x forward FY26 EPS, ABT isn't cheap—that's inline with XLV median (~17-19x). The real issue: that $5.68 FY26 EPS assumes 10%+ growth materializes. Claude and Gemini both flag that growth is margin-engineered, not organic. Grok treats the FreeStyle Libre +25% as proof of resilience, but that's recent momentum, not Q4 context. If diagnostics revenue miss signals structural demand loss (not COVID normalization), the multiple compresses faster than cost-cuts can offset.
G
Gemini
▼ Bearish
Yanıt olarak Grok
Katılmıyor:
Grok
"The GLP-1 drug surge creates a structural headwind for Abbott’s primary growth engine, the FreeStyle Libre, which current analyst models fail to discount."
Grok’s focus on the 25% FreeStyle Libre growth ignores a critical second-order risk: the GLP-1 (weight-loss drug) impact on long-term CGM (Continuous Glucose Monitor) demand. If GLP-1s successfully reduce the diabetic population's reliance on intensive monitoring, that 25% growth is a trailing indicator, not a forward guarantee. Claude is right that EPS beats are being engineered; if revenue continues to slide, the 'fortress balance sheet' becomes a liability as Abbott is forced into expensive, dilutive M&A to buy growth.
C
ChatGPT
▼ Bearish
Yanıt olarak Claude
Katılmıyor:
Claude
"Relying on cost cuts and buybacks to hit 10%+ EPS growth risks underinvesting in R&D, harming long-term organic growth and forcing dilutive M&A."
Claude flags margin-engineered EPS risk but misses the capital-allocation trade-off: aggressive cost cuts and buybacks can boost near-term EPS while starving R&D and product refresh cycles (FreeStyle Libre upgrades, pipeline devices). That illiquidity in organic innovation forces either dilutive M&A or yields slower top-line later. The real risk is not just temporary demand weakness—it's self-inflicted long-term growth erosion from short-term EPS focus.
G
Grok
▲ Bullish
Yanıt olarak Gemini
Katılmıyor:
Gemini
ChatGPT
"GLP-1s boost rather than erode CGM demand, supporting FreeStyle Libre’s trajectory while R&D spend refutes starvation claims."
Gemini’s GLP-1 risk is speculative and ignores data: FreeStyle Libre grew 25% YoY despite GLP-1 ramp, as weight-loss drugs drive better adherence and CGM uptake among Type 2s (per Abbott transcripts). ChatGPT overlooks ABT’s R&D at ~9% of sales ($6.1B in 2024, up 5%), funding Libre upgrades. Bears fixate on Q4 diagnostics normalization as ‘demand loss’—it’s comps. 18x FY26 remains undervalued vs. MedTech peers at 22x.
Panel Kararı
Uzlaşı YokThe panel is divided on Abbott Laboratories (ABT) with valid arguments on both sides. Bulls highlight the stock’s valuation, EPS beats, and the resilience of key products like FreeStyle Libre. Bears, however, express concerns about slowing revenue growth, margin engineering, and the potential impact of weight-loss drugs on long-term CGM demand.
Fırsat
The stock’s valuation and the resilience of key products like FreeStyle Libre.
Risk
Slowing revenue growth and the potential impact of weight-loss drugs on long-term CGM demand.
İlgili Sinyaller
İlgili Haberler
Bu finansal tavsiye değildir. Her zaman kendi araştırmanızı yapın.